849243-26-1

Basic information

• Product Name: 1-Pyrrolidineheptanenitrile, 2-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]-5-oxo-, (2R)-
• CAS NO: 849243-26-1
• Molecular Formula: C21H24F2N2O2
• Molecular Weight: 374.431
• Mol File: 849243-26-1.mol

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidineheptanenitrile, 2-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]-5-oxo-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidineheptanenitrile, 2-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]-5-oxo-, (2R)-(849243-26-1)
• EPA Substance Registry System: 1-Pyrrolidineheptanenitrile, 2-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]-5-oxo-, (2R)-(849243-26-1)

Safety Data

• Hazardous Substances Data: 849243-26-1(Hazardous Substances Data)

Upstream product

• 346672-94-4 7-[(2R)-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-oxopyrrolidin-1-yl]heptanenitrile 
• 346672-95-5 7-[(2R)-2-hydroxymethyl-5-oxopyrrolidin-1-yl]heptanenitrile 
• 128899-30-9 (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
• 2248-46-6 ethyl 2,2-difluoro-2-phenylacetate 
• 20965-27-9 7-bromo-heptanonitrile 
• 1603-79-8 phenylglyoxylic acid ethyl ester 
• 346672-63-7 7-[(2R)-2-formyl-5-oxopyrrolidin-1-yl]heptanenitrile 
• 82302-97-4 dimethyl (3,3-difluoro-2-oxo-3-phenylpropyl)phosphonate 

Downstream Products

• 849243-29-4 7-{(2R)-2-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-1-yl]-5-oxopyrrolidin-1-yl}heptanenitrile 
• 849243-27-2 7-{(2R)-2-[(1E,3S)-4,4-difluoro-3-hydroxy-4-phenylbut-1-en-1-yl]-5-oxopyrrolidin-1-yl}heptanenitrile 

Relevant articles and documents

Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist

An optimized analog of prostaglandin E2 which incorporates a γ-lactam in place of the cyclopentanone ring and which incorporates metabolically stabilized side chains, has been identified and shown to exhibit potent and selective EP4 receptor ag

1,5-DISTRIBUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors of formula (I), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of the patient.